Antiplatelet Compounds with Faster Onset and Improved Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic agents like clopidogrel have limitations such as interpatient variability, resistance, slow onset of action, low solubility, and lack of an injection formulation, which hinder effective inhibition of platelet aggregation in vascular diseases.
Innovation Solution
Development of novel compounds with specific chemical structures that inhibit platelet aggregation, including pharmaceutical compositions and methods for treating vascular diseases by administering these compounds, which offer improved solubility, faster onset of action, and reduced interpatient variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If clopidogrel is used as an antithrombotic agent, then platelet aggregation can be inhibited, but the onset of action is slow (2 hours after loading dose)
Solution Approach 1:
The patent applies preliminary action by designing compounds that are pre-activated or require minimal metabolic transformation before exerting their antiplatelet effect. The novel compounds of Formula (I) are structured to bypass the slow two-step oxidation process required for clopidogrel activation, enabling faster binding to the P2Y12 receptor and quicker inhibition of platelet aggregation.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of clopidogrel to create compounds with improved pharmacokinetic properties. The specific substitutions at positions R1-R4 and the modified heterocyclic ring system in Formula (I) alter the molecule's solubility, metabolic stability, and receptor binding kinetics, resulting in faster onset of action compared to parenteral clopidogrel.
2Reliability
If clopidogrel is administered to achieve adequate platelet inhibition, then a high loading dose (600 mg) is required, but this increases the risk of adverse effects and drug-drug interactions
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure to improve metabolic stability and reduce dependence on CYP2C19 enzyme polymorphisms. The novel compounds maintain reliable platelet inhibition at lower doses by optimizing the balance between metabolic clearance and active metabolite formation, thereby reducing the need for high loading doses and associated adverse effects.
Solution Approach 2:
The patent employs this principle by designing compounds that achieve their therapeutic effect more rapidly and reliably, allowing for shorter duration of high-dose therapy. The improved pharmacokinetic profile enables effective platelet inhibition with reduced cumulative exposure to high doses, minimizing the window of vulnerability to adverse effects and drug interactions.
3Ease of operation
If clopidogrel is used for acute treatment, then an injection formulation would be beneficial, but clopidogrel has low solubility in aqueous solution and no injection formulation is available
Solution Approach 1:
The patent applies parameter changes by introducing polar substituents and modifying the heterocyclic ring system in Formula (I) to enhance aqueous solubility. These structural modifications increase the compound's hydrophilicity, enabling the development of injectable formulations suitable for acute treatment while maintaining the desired antiplatelet activity.
Solution Approach 2:
The patent employs composite materials principles by designing molecules that combine the lipophilic aromatic core necessary for P2Y12 receptor binding with hydrophilic substituents that improve solubility. This composite molecular structure allows the compound to exhibit both adequate oral bioavailability and sufficient aqueous solubility for parenteral administration.
4Reliability
If clopidogrel is administered, then platelet P2Y12 receptor can be inhibited, but interpatient variability in antithrombotic effects occurs due to different CYP2C19 expression levels
Solution Approach 1:
The patent applies parameter changes by designing compounds with modified metabolic pathways that are less dependent on CYP2C19 enzyme activity. The novel structures in Formula (I) are engineered to undergo alternative metabolic transformations or exhibit reduced metabolic clearance, thereby minimizing the impact of CYP2C19 polymorphisms and achieving more consistent antiplatelet effects across different patient populations.
Data Source
AI summary
The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administration of these compounds or the pharmaceutical compositions.